---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-092414"
form_type: "8-K"
ticker: null
cik: "0001309057"
company_name: "China Health Industries Holdings, Inc."
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:36:15.861202+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# China Health Industries closes acquisition of HempCan for ~$40.9M

## Summary
- Closed acquisition of 100% of Heilongjiang HempCan Pharmaceuticals on Dec 1, 2023.
- Total cash consideration of RMB295M (~$40.9M) paid to sellers Xin Sun and Kai Sun.
- Transaction was previously announced in Form 8-K filed July 3, 2023.
- Humankind, a wholly owned subsidiary, is the acquiring entity.

## SEC filing metadata
- accession: 0001213900-23-092414
- form_type: 8-K
- cik: 0001309057
- company_name: China Health Industries Holdings, Inc.
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1309057/000121390023092414/0001213900-23-092414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1309057/000121390023092414/ea189444-8k_chinahealth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-092414
- JSON: https://secwatch.observer/filing/0001213900-23-092414.json
- Plain text: https://secwatch.observer/filing/0001213900-23-092414.txt

## Key facts
- M&A Transactions
  China Health Industries Holdings, Inc. completed an acquisition involving Mr. Xin Sun and Mr. Kai Sun for RMB295 million (approximately $40,916,530) (closed 2023-12-01).
  - Action: acquisition
  - Counterparty: Mr. Xin Sun and Mr. Kai Sun
  - Consideration: RMB295 million (approximately $40,916,530)
  - Closing: 2023-12-01
  source text: and the changes of business registration have been completed. As the consideration for the Acquisition, the Company paid the Sellers an aggregate cash consideration of RMB295 million (approximately $40,916,530) in exchange for 100% equity ownership of HempCan. The English translation of the Agreements are filed herein as Exhibit 10.1 and Exhibit 10.2 and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1309057/000121390023092414/0001213900-23-092414-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.